{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:11:07Z","timestamp":1779246667594,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030820","name":"Drug Discovery Center, College of Pharmacy, Health Science Center, University of Tennessee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030820","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119353","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:00:40Z","timestamp":1775844040000},"page":"119353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel colchicine-binding site inhibitor suppresses triple-negative breast cancer growth and metastasis and synergizes with anti-PD-L1 immunotherapy in an immunogenic cancer model"],"prefix":"10.1016","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-7580","authenticated-orcid":false,"given":"Kelli L.","family":"Adeleye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damilola","family":"Oluwalana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2118-4019","authenticated-orcid":false,"given":"Raisa","family":"Krutilina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-5152","authenticated-orcid":false,"given":"Yang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7617-9906","authenticated-orcid":false,"given":"Satyanarayana","family":"Pochampally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1884-4204","authenticated-orcid":false,"given":"Lily","family":"Waltz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1313-9207","authenticated-orcid":false,"given":"Gustavo A.","family":"Miranda-Carboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duane D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6937-943X","authenticated-orcid":false,"given":"Tiffany N.","family":"Seagroves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-4474","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2026.119353_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin. May-Jun."},{"key":"10.1016\/j.biopha.2026.119353_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.biopha.2026.119353_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jbi\/wbaa110","article-title":"Molecular subtypes of breast cancer: a review for breast radiologists","volume":"3","author":"Johnson","year":"2020","journal-title":"J. Breast Imaging"},{"issue":"4","key":"10.1016\/j.biopha.2026.119353_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040916","article-title":"The landscape of targeted therapies in TNBC","volume":"12","author":"Vagia","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119353_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104683","article-title":"Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer","volume":"153","author":"Deepak","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119353_bib6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41598-024-84785-3","article-title":"Predictive markers of rapid disease progression and chemotherapy resistance in triple-negative breast cancer patients following postoperative adjuvant therapy","volume":"15","author":"Ma","year":"2025","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.biopha.2026.119353_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101791","article-title":"Overall survival and prognostic factors in metastatic triple-negative breast cancer: a national cancer database analysis","volume":"16","author":"Kesireddy","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.biopha.2026.119353_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.biopha.2026.119353_bib9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","article-title":"Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119353_bib10","article-title":"Paclitaxel resistance in breast cancer: current challenges and recent advanced therapeutic strategies","volume":"43","author":"Abouzeid","year":"2025","journal-title":"Cancer Treat. Res. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2026.119353_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11523-024-01125-1","article-title":"Second-line treatment options for patients with metastatic triple-negative breast cancer: a review of the clinical evidence","volume":"20","author":"Garc\u00eda-Saenz","year":"2025","journal-title":"Target Oncol."},{"key":"10.1016\/j.biopha.2026.119353_bib12","first-page":"2020","article-title":"The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment","volume":"11","author":"Hudson","year":"2020","journal-title":"Rev. Front. Immunol."},{"issue":"23","key":"10.1016\/j.biopha.2026.119353_bib13","doi-asserted-by":"crossref","first-page":"19393","DOI":"10.18632\/oncotarget.5107","article-title":"The anticancer immune response of anti-PD-1\/PD-L1 and the genetic determinants of response to anti-PD-1\/PD-L1 antibodies in cancer patients","volume":"6","author":"Sui","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119353_bib14","first-page":"2017","article-title":"PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response?","volume":"8","author":"Xu-Monette","year":"2017","journal-title":"Rev. Front. Immunol."},{"issue":"19","key":"10.1016\/j.biopha.2026.119353_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194682","article-title":"PD-1\/PD-L1 inhibitors response in triple-negative breast cancer: can long noncoding RNAs be associated?","volume":"15","author":"Mathias","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.biopha.2026.119353_bib16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119353_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12957-021-02361-9","article-title":"Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy","volume":"19","author":"Oner","year":"2021","journal-title":"World J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119353_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010104","article-title":"Mechanisms and strategies to overcome PD-1\/PD-L1 blockade resistance in triple-negative breast cancer","volume":"15","author":"Chen","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.biopha.2026.119353_bib19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1172\/JCI96113","article-title":"Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression","volume":"128","author":"Lin","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.biopha.2026.119353_bib20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oncolo\/oyae006","article-title":"Impact of Increasing PD-L1 Levels on Outcomes to PD-1\/PD-L1 inhibition in patients with NSCLC: a pooled analysis of 11 prospective clinical trials","volume":"29","author":"Vallejo","year":"2024","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.biopha.2026.119353_bib21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1025513106330","article-title":"Microtubules, microtubule-interfering agents and apoptosis","volume":"8","author":"Mollinedo","year":"2003","journal-title":"Apoptosis"},{"issue":"2","key":"10.1016\/j.biopha.2026.119353_bib22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/1535-7163.MCT-19-0536","article-title":"An orally available tubulin inhibitor, VERU-111, suppresses triple-negative breast cancer tumor growth and metastasis and bypasses taxane resistance","volume":"19","author":"Deng","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119353_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217011","article-title":"Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer","volume":"597","author":"Oluwalana","year":"2024","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.biopha.2026.119353_bib24","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/acsptsci.2c00108","article-title":"Design, synthesis, and biological evaluation of pyrimidine dihydroquinoxalinone derivatives as tubulin colchicine site-binding agents that displayed potent anticancer activity both in vitro and in vivo","volume":"6","author":"Pochampally","year":"2023","journal-title":"ACS Pharm. Transl. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2026.119353_bib25","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/00220345241261982","article-title":"Novel antimitotic agent SP-1-39 inhibits head and neck squamous cell carcinoma","volume":"103","author":"Adeleye","year":"2024","journal-title":"J. Dent. Res"},{"issue":"5","key":"10.1016\/j.biopha.2026.119353_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1179\/joc.2011.23.5.295","article-title":"Paclitaxel induced B7-H1 expression in cancer cells via the MAPK pathway","volume":"23","author":"Gong","year":"2011","journal-title":"J. Chemother."},{"issue":"22","key":"10.1016\/j.biopha.2026.119353_bib27","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119353_bib28","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119353_bib29","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1038\/s41467-023-40270-5","article-title":"Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119353_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1182601","article-title":"AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses","volume":"14","author":"Meng","year":"2023","journal-title":"Front Immunol."},{"issue":"28","key":"10.1016\/j.biopha.2026.119353_bib31","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1038\/onc.2013.341","article-title":"The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2","volume":"33","author":"Choi","year":"2014","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2026.119353_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2011.01.021","article-title":"Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles","volume":"152","author":"Gao","year":"2011","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.biopha.2026.119353_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14572","article-title":"Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice","volume":"8","author":"Lau","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119353_bib34","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.2147\/OTT.S294129","article-title":"Remodels the immunosuppressive tumor microenvironment by combination of bacillus calmette-gu\u00e9rin and anti-PD-L1 in an orthotopic triple-negative breast cancer mouse model","volume":"14","author":"Lu","year":"2021","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.biopha.2026.119353_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101405","article-title":"Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response","volume":"20","author":"Rupp","year":"2022","journal-title":"Transl. Oncol."},{"issue":"7050","key":"10.1016\/j.biopha.2026.119353_bib36","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature03799","article-title":"Genes that mediate breast cancer metastasis to lung","volume":"436","author":"Minn","year":"2005","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2026.119353_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/nano11020515","article-title":"Therapeutic efficacy and biodistribution of paclitaxel-bound amphiphilic cyclodextrin nanoparticles: analyses in 3D tumor culture and tumor-bearing animals in vivo","volume":"11","author":"Varan","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.biopha.2026.119353_bib38","first-page":"2021","article-title":"Self-assembly engineering nanodrugs composed of paclitaxel and curcumin for the combined treatment of triple negative breast cancer","volume":"9","author":"Zuo","year":"2021","journal-title":"Orig. Res. Front. Bioeng. Biotechnol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119353_bib39","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1038\/s43018-025-01029-7","article-title":"A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer","volume":"6","author":"Wang","year":"2025","journal-title":"Nat. Cancer"},{"issue":"15","key":"10.1016\/j.biopha.2026.119353_bib40","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.devcel.2025.03.004","article-title":"KIF2C promotes paclitaxel resistance by depolymerizing polyglutamylated microtubules","volume":"60","author":"Pao","year":"2025","journal-title":"Dev. Cell"},{"issue":"17","key":"10.1016\/j.biopha.2026.119353_bib41","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.246702","article-title":"The role of the \u03b1-tubulin acetyltransferase \u03b1TAT1 in the DNA damage response","volume":"133","author":"Ryu","year":"2020","journal-title":"J. Cell Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119353_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/cdd.2017.170","article-title":"Anti-apoptotic BCL-2 family members in development","volume":"25","author":"Opferman","year":"2018","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.biopha.2026.119353_bib43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13046-018-0999-5","article-title":"Therapeutic impact of Nintedanib with paclitaxel and\/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer","volume":"38","author":"Reguera-Nu\u00f1ez","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119353_bib44","article-title":"Discovery of potent and brain-penetrable tubulin inhibitors that effectively suppress breast cancer brain metastasis","author":"Krutilina","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119353_bib45","first-page":"319","article-title":"Body condition scoring: a rapid and accurate method for assessing health status in mice","volume":"49","author":"Ullman-Culler\u00e9","year":"1999","journal-title":"Lab Anim. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2026.119353_bib46","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41419-020-2567-0","article-title":"Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment","volume":"11","author":"Serpico","year":"2020","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119353_bib47","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1038\/s41598-022-07153-z","article-title":"Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment","volume":"12","author":"Jin","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2026.119353_bib48","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1172\/JCI96061","article-title":"PD-L1 on host cells is essential for PD-L1 blockade\u2013mediated tumor regression","volume":"128","author":"Tang","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.biopha.2026.119353_bib49","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.biopha.2026.119353_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.biopha.2026.119353_bib51","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119353_bib52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.celrep.2018.12.014","article-title":"Microtubule-driven stress granule dynamics regulate inhibitory immune checkpoint expression in T cells","volume":"26","author":"Franchini","year":"2019","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.biopha.2026.119353_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102414","article-title":"Cytotoxic T-lymphocyte antigen-4 in colorectal cancer: another therapeutic side of capecitabine","volume":"13","author":"Derakhshani","year":"2021","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.biopha.2026.119353_bib54","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03baB to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.biopha.2026.119353_bib55","doi-asserted-by":"crossref","first-page":"7877","DOI":"10.1021\/acs.jmedchem.8b00827","article-title":"Structural modification of the 3,4,5-trimethoxyphenyl moiety in the tubulin inhibitor VERU-111 leads to improved antiproliferative activities","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:58:04Z","timestamp":1779245884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226003860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":55,"alternative-id":["S0753332226003860"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119353","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel colchicine-binding site inhibitor suppresses triple-negative breast cancer growth and metastasis and synergizes with anti-PD-L1 immunotherapy in an immunogenic cancer model","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119353"}}